New pill aims to cut lung infections in bronchiectasis patients
NCT ID NCT07577804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a daily tablet called florensocatib can reduce the number of lung flare-ups in people with bronchiectasis, a chronic lung condition. About 904 participants aged 12 to 85 will be randomly assigned to receive either the drug or a placebo for up to 78 weeks, followed by an open-label phase where everyone gets the drug. The study also looks at lung function, quality of life, and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Florensocatib (CHF10196) tablets
- What this could lead to
- If it works, this could provide a new daily treatment to reduce lung infections and flare-ups in people with bronchiectasis.
- What could go wrong
- This is a large phase 3 trial, but the drug is still experimental. It may not reduce flare-ups significantly, and side effects are possible. Results will take years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gum treatment may lower lung flare-ups in bronchiectasis patients
- Can a daily pill cut dangerous lung Flare-Ups in bronchiectasis?
- Lung inflammation may speed heart aging, study investigates
- Scientists track hidden threat of antibiotic resistance in lung patients
- Handheld breath test could spot lung disease early
- Sauna therapy could slash antibiotic use in chronic lung disease